Liquidia Corporation (LQDA)

Market Cap	2.53B
Revenue (ttm)	69.22M
Net Income (ttm)	-124.09M
Shares Out	87.00M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	14.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,173,492
Open	28.06
Previous Close	28.56
Day's Range	27.76 - 29.51
52-Week Range	9.93 - 30.88
Beta	0.51
Analysts	Strong Buy
Price Target	37.40 (+28.48%)
Earnings Date	Nov 3, 2025

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2024, Liquidia's revenue was $14.00 million, a decrease of -19.97% compared to the previous year's $17.49 million. Losses were -$130.39 million, 66.1% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $37.4, which is an increase of 28.48% from the latest price.

Price Target

$37.4

(28.48% upside)

Analyst Consensus: Strong Buy